CTRI/2023/08/056674已完成Unknown
An open label, randomized, single dose, two-treatment, two -way crossover, oral bioavailability study of investigational product containing glutathione, in healthy, adult, human subjects under fasting conditions. - nil
YourZooki holdings Ltd0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Normal, healthy, adult, male and female human subjects of age between 18-65 years with a body mass index range between 18.50 kg/m2 to 24.99 kg/m2.
- •2.Subject agrees avoid Glutathione containing medications and dietary supplements from screening until last visit.
- •3.Subject agrees to avoid high activity physical exercise 72.00 hours prior to last visit
- •4.Subjects who have no evidence of underlying disease during screening and check-in and whose screening is performed within 29 days of check in.
- •5.Subjects whose screening laboratory values are within normal limits or considered by the physician or principal/clinical investigator to be of no clinical significance.
- •6.Healthy as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, musculoskeletal and central nervous systems) and vital sign assessments.
- •7.Generally healthy as documented by 12-lead electrocardiogram (ECG), X-Ray and clinical laboratory assessments.
- •8.Non- smokers or ex-smokers. Ex-smokers are defined as someone who has completely stopped smoking for at least the past 03 months.
- •9.Willing to consume ova-lacto vegetarian diet.
- •10.Willing to comply to all requirements of this study protocol as well as instructed by the study personnel
- •11.Female subjects within normal limits or clinically non-significant laboratory evaluation results for FSH and LH.
- •12.Generally healthy as documented by gynecological examination and breast examination (for female subjects during Period-I check-in only).
- •13.Female subjects of childbearing potential;
- •a.Practicing an acceptable non-hormonal contraceptive method of birth control after consulting with principal investigator; and/or
- •b.Surgically sterile (bilateral tubal ligation)
排除标准
- •1.Evidence of allergy or known hypersensitivity to Glutathione or other related drugs or other related drugs.
- •2.Subjects with hepatic encephalopathy, cholestasis, myasthenia, pre-existing liver disease, alcohol abuse, existing tinnitus, renal or liver impairment and pre-existing gallbladder disease.
- •3.Any major illness in the last three months or any significant ongoing chronic medical illness.
- •4.Any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, Musculoskeletal, respiratory, central nervous system, diabetes, psychosis or any other body system.
- •5.History of alcohol addiction or abuse.
- •6.Malabsorption syndrome that affects Glutathione metabolism.
- •7.Heart failure, angina pectoris, ventricular arrhythmias or atrial fibrillation with >100/min ventricular rate.
- •8.Gastrointestinal bleeding in past three months.
- •9.Uncontrolled diabetes mellitus.
- •10.Active psychiatric disorder, intention for suicidal, disorders with Unconsciousness.
- •11.Psychopathic disorder, lack of cooperation.
- •12.Chronic obstructive lung disease or active smoking (more than 2 cigarettes in the past 6 months)
- •13.Taking more than 100 mg Glutathione daily within 2 weeks to screening.
- •14.Consumption of caffeine and /or Xanthine containing products (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.), tobacco containing products for at least 24.00 hours prior to check-in and throughout the entire study
- •15.Consumption of grapefruit and its juice and poppy containing foods for at least 72.00 hours prior to check-in and throughout the study.
- •16.Subjects who taken any prescription medications, over the counter medicinal products, herbal medications within 14 days prior to study check in and throughout the study.
- •17.History of dehydration from diarrhea, vomiting or any other reason within a period of 24.00 hours prior to study check-in of each period.
- •18.An unusual or abnormal diet within 48.00 hours prior to study check-in of each period, for whatever reason e.g. because of fasting due to religious reasons.
- •19.Subject who had participated in any other study within the 90 days of check-in.
- •20.History of difficulty in swallowing.
- •21.Positive results for drugs of abuse (Marijuana-THC, amphetamine-AMP, barbiturates-BAR, cocaine-COC, benzodiazepines-BZD and morphine-MOR) in urine prior to check-in of this study period.
- •22.Positive results for alcohol breath test prior to check-in of any study period
- •23.Any blood donation / excess blood loss within 90 days of check-in.
- •24.Systolic blood pressure less than 90mrn Hg or more than 140mmHg and diastolic blood pressure less than 60 mmHg or more than 90 mmHg.
- •25.Ingestion of any hormonal agent at any time within 14 days prior to start of study check-in.
- •26.Female subjects demonstrating a positive pregnancy screen.
- •27.Female subjects whose menstruation cycle coincides with the study periods.
- •28.Female subjects who are currently lactating.
- •29.Females likely to become pregnant during conducting of the study
- •30.Use of hormone replacement therapy for a Period of 06 months prior to dosing.
- •31.Use of any oral contraceptives including estrogen and progestin combined pills and progestin only pills within 28 days prior to period
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapsesMultiple sclerosisMedDRA version: 12.0Level: PTClassification code 10028245Term: <Manually entered code. Term in E.1.1>EUCTR2004-000555-42-DKSanofi-aventis US, Inc1,080
进行中（未招募）
1 期
To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's diseaseEUCTR2016-002976-28-ITOVARTIS PHARMA AG1,144
进行中（未招募）
1 期
Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CDZ173Primary Sjögren's syndromeMedDRA version: 19.0Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-004616-12-DEovartis Pharma Services AG30
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney diseaseType II Diabetes Mellitus and Diabetic Kidney DiseaseMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-000950-39-ITBAYER AG12,800
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-weektreatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of surinabant: 2.5, 5 and 10mg/day as an aid to smoking cessation in cigarette smokers - SURSMOKEAid to smoking cessation in cigarette smokersMedDRA version: 8.1Level: LLTClassification code 10057852Term: Nicotine dependenceEUCTR2006-005334-21-DEsanofi-aventis recherche et developpement805